Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
PRAX 
Praxis Precision Medicines Inc (PRAX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: PRAX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
12 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $99.67
1 Year Target Price $99.67
| 8 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 0.53% | Avg. Invested days 36 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 987.47M USD | Price to earnings Ratio - | 1Y Target Price 99.67 |
Price to earnings Ratio - | 1Y Target Price 99.67 | ||
Volume (30-day avg) 12 | Beta 2.63 | 52 Weeks Range 26.70 - 91.83 | Updated Date 08/29/2025 |
52 Weeks Range 26.70 - 91.83 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -12.4 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-04 | When - | Estimate -3.25 | Actual -3.31 |
Profitability
Profit Margin - | Operating Margin (TTM) -3497.57% |
Management Effectiveness
Return on Assets (TTM) -37.98% | Return on Equity (TTM) -60.98% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 686948044 | Price to Sales(TTM) 127.17 |
Enterprise Value 686948044 | Price to Sales(TTM) 127.17 | ||
Enterprise Value to Revenue 88.47 | Enterprise Value to EBITDA -6.86 | Shares Outstanding 21045800 | Shares Floating 15644592 |
Shares Outstanding 21045800 | Shares Floating 15644592 | ||
Percent Insiders 0.16 | Percent Institutions 118.59 |
Upturn AI SWOT
Praxis Precision Medicines Inc
Company Overview
History and Background
Praxis Precision Medicines, Inc. is a biopharmaceutical company founded in 2015. It focuses on developing therapies for central nervous system (CNS) disorders. It has evolved through preclinical and clinical development programs, aiming to address unmet needs in brain disorders.
Core Business Areas
- Neurology: Focuses on developing therapies for neurological disorders such as epilepsy, Parkinson's disease, and essential tremor.
- Psychiatry: Developing therapies for psychiatric disorders like depression and anxiety.
Leadership and Structure
The leadership team includes key executives in research and development, clinical operations, and corporate management. The organizational structure is typical of a biotech company, with departments focused on drug discovery, clinical trials, and regulatory affairs.
Top Products and Market Share
Key Offerings
- PRAX-944: A T-type calcium channel blocker being developed for Essential Tremor. Currently in clinical trials. Market share is currently 0% as the product is not yet approved. Competitors include Propranolol, Primidone, and deep brain stimulation (DBS).
- PRAX-562: Developing for SCN20A loss-of-function related disorders. Currently in clinical trials. Market share is currently 0% as the product is not yet approved. There are currently no approved therapies for these disorders, representing a high unmet need.
Market Dynamics
Industry Overview
The biopharmaceutical industry for CNS disorders is characterized by high unmet needs, significant research and development investments, and a complex regulatory landscape. There is a growing market for novel therapies due to the increasing prevalence of neurological and psychiatric conditions.
Positioning
Praxis Precision Medicines is positioned as a company focused on precision medicine for CNS disorders, using genetic insights to develop targeted therapies. Its competitive advantage lies in its specific focus on genetically-defined patient populations.
Total Addressable Market (TAM)
The TAM for CNS disorder therapeutics is estimated to be in the tens of billions of dollars annually. Praxis is positioned to capture a share of this market by developing targeted therapies for specific genetic subtypes, representing a potentially significant revenue opportunity if trials are successful and approved.
Upturn SWOT Analysis
Strengths
- Targeted approach to CNS disorders
- Strong scientific team
- Pipeline of novel therapies
- Focus on precision medicine
Weaknesses
- Early-stage clinical development
- High cash burn rate
- Dependence on clinical trial outcomes
- Limited revenue generation
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline through acquisitions or in-licensing
- Successful clinical trial results leading to regulatory approval
- Growing awareness of genetic contributions to CNS disorders
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Market access and reimbursement challenges
Competitors and Market Share
Key Competitors
- UCB (UCBJF)
- Jazz Pharmaceuticals (JAZZ)
- Eisai (ESALY)
Competitive Landscape
Praxis faces competition from established pharmaceutical companies with broader product portfolios and greater financial resources. Its competitive advantage lies in its targeted approach and focus on genetically-defined patient populations.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been characterized by the expansion of its pipeline and advancement of clinical programs.
Future Projections: Future growth projections depend on the successful development and commercialization of its lead drug candidates. Analyst estimates vary based on the perceived probability of success for these programs.
Recent Initiatives: Recent initiatives include advancing its lead compounds through clinical trials, expanding its research collaborations, and strengthening its intellectual property portfolio.
Summary
Praxis Precision Medicines is a high-risk, high-reward biotech company focused on precision medicines for CNS disorders. Its success hinges on the outcome of its clinical trials and regulatory approvals. Investors should be aware of the significant risks associated with drug development, including clinical trial failures and regulatory hurdles. However, positive results could drive substantial value creation.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Praxis Precision Medicines Inc. website
- SEC Filings
- Analyst reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be made based on individual risk tolerance and thorough due diligence. Market share data is estimated based on available information and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Praxis Precision Medicines Inc
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2020-10-16 | President, CEO & Director Mr. Marcio Silva De'Souza M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 116 | Website https://praxismedicines.com |
Full time employees 116 | Website https://praxismedicines.com | ||
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance. The company's platforms include cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and solidus to discover and develop antisense oligonucleotide. It also develops Ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase 3 clinical trial for the treatment of essential tremor; Vormatrigine, a small molecule targeting the hyperexcitable state of sodium-channels in the brain to treat focal onset epilepsy; Relutrigine for the treatment of developmental and epileptic encephalopathies; PRAX-020 to treat KCNT1; and PRAX-050. In addition, the company develops Elsunersen, a clinical-stage ASO designed to regulate NaV1.2 expression for the treatment of SCN2A-DEE; PRAX-080 that targets PCDH19-related developmental epilepsy; PRAX-090 for targeting SYNGAP1 loss-of-function; and PRAX-100 that targets SCN2A LoF mutations. It has a license agreement with RogCon Inc.; and research collaboration and license agreement with Ionis Pharmaceuticals, Inc. Praxis Precision Medicines, Inc. was incorporated in 2015 and is based in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.